What is the actual difference between 5mg, 10mg, and 30mg vials?
The difference is simply the total amount of Semax peptide contained in the vial before anything was added to it. A 5 mg vial contains 5 milligrams of lyophilized peptide sealed inside. A 10 mg vial contains 10 milligrams. A 30 mg vial contains 30 milligrams. That’s the only difference at the vial level.
None of them represent different strengths of Semax in a chemical sense. The molecule itself is identical regardless of the vial size. What changes is simply the total amount of peptide involved and, consequently, how many doses can realistically be drawn from a single vial before it runs out.
You can compare this to buying flour in a 1-kilogram package versus a 5-kilogram package. It’s the same flour in both cases. The only choice you’re making is how much of the product you want to have on hand and how it will be used. A 30-mg vial provides six times more total peptide than a 5-mg vial, which naturally means it can provide significantly more individual doses. However, this does not mean that every dose from a 30-mg vial is in any way stronger than a dose from a 5-mg vial. The strength of a dose depends entirely on how much was actually drawn up and administered per dose, not on the size of the vial from which that dose came.
Which vial size should you choose?
It really comes down to practical math, not any biological considerations. For a short trial period or a single 10-day course, a smaller vial, such as a 5 mg one, can provide everything you need without leaving a peptide sitting in the fridge for weeks. For long-term or repeated use, a 30-mg vial works out to a lower cost per milligram and means less frequent purchasing and reconstitution. The trade-off is the need to store a larger reconstituted volume for a longer period, which raises its own considerations regarding storage and stability, discussed elsewhere.
There is also a practical aspect of dosing precision to consider. A larger vial, after reconstitution with the appropriate amount of water, can actually make it easier to draw up very small, precise doses. This is because more total liquid volume is available to work with for the same target dose in micrograms. Small doses drawn from a small total volume can be more difficult to accurately measure with a standard syringe.
What is Semax 10 mg actually used for?
There isn't any special or distinct application specifically tied to the 10mg size. It's simply one of the more commonly sold vial sizes, likely because it hits a reasonable middle ground between a smaller 5mg option and a larger 30mg option in terms of total peptide quantity and cost. Actual dosing and intended use are determined by how it is reconstituted and dosed, rather than anything inherent to the „10mg” label itself.
What does a vial of Semax actually look like?
A typical Semax vial is a small glass container, usually holding somewhere between 2 to 10 milliliters of space. It is sealed with a rubber stopper under a metal or plastic cap, which needs to be removed or pierced with a needle for reconstitution. Inside, before any liquid is added, you will see the lyophilized peptide. It typically appears as a small amount of white or cream-colored powder, sometimes compressed into a loaf-like shape at the bottom of the vial rather than being a fine, loose powder. This loaf-like appearance is completely normal and simply reflects how the lyophilization process works.
What is the difference between the Semax 0.1% and 1% solutions?
This is a different type of specification than the vial sizes discussed above. It refers to the concentration of the liquid as prepared, rather than the amount of dry powder. The 0.1% solution contains 1 milligram of Semax per milliliter of liquid. The 1% solution contains 10 milligrams per milliliter—a tenfold difference in concentration. These percentage-based labels reflect how Semax has traditionally been formulated in Russian clinical practice. The 1% solution is generally used for higher-dose applications, such as stroke treatment. The 0.1% solution is used when lower, more precisely adjusted doses are appropriate, as in certain treatment protocols for optic nerve diseases [1], [2].
When working with a vial of dry powder—5 mg, 10 mg, or 30 mg — rather than with a pre-prepared percentage solution, there is flexibility to reconstitute the medication to any concentration that best suits the intended dosage, rather than being limited to a fixed strength of 0.1% or 1%.
What is Semax powder and why is it in this form?
Semax powder is a lyophilized, or freeze-dried, form of the peptide. It is the same molecule found in the liquid nasal spray, only with all the water removed, leaving the peptide in a dry, stable state. Peptides are inherently more fragile once dissolved in water. The presence of water allows for a chemical process called hydrolysis, which gradually breaks down the peptide bonds holding the molecule together. Removing the water through lyophilization essentially places the peptide in a kind of suspended, more stable state. This is precisely why manufacturers ship and store Semax this way, rather than as a pre-made liquid, whenever possible.
Which is better, Semax powder or liquid?
No form is inherently better. They simply serve different purposes at different stages of use. Powder is better for storage and shelf life, because the dry state resists degradation much more effectively than a liquid solution. The liquid is what is actually needed to administer a dose, whether via a nasal spray or an injection, since dry powder obviously cannot be sprayed or injected directly.
The practical answer for most people is: use the powder for long-term storage, and the liquid only for the period that the batch is actively being used. That's precisely why reconstitution exists as a process in the first place. It intentionally transforms a stable, storage-friendly form into a usable but more fragile ready-to-serve form, only when it's actually time to start using it.
How do you use Semax powder directly?
Semax powder is never administered directly to the body in its dry form. It must first be reconstituted into a liquid, whether for nasal use as drops or a spray, or for subcutaneous injection. The powder itself, sitting dry in a vial, is not something that would ever be applied to the nose or injected in that state. The entire purpose of the powder form is to sit in stable storage until it is time to dissolve it in bacteriostatic water and turn it into something deliverable.
What is the real difference between Semax powder and the ready-made nasal spray?
The molecule inside is identical in both cases. The actual difference is simply the timing and who performed the reconstitution. The ready-to-use nasal spray has already undergone the conversion process from powder to liquid, presumably under more controlled, possibly pharmaceutical-grade conditions, and is ready to use straight out of the package. The powder requires you to personally perform that reconstitution step before it's of any use.
The trade-off is this: a ready-to-use spray has already begun its liquid-phase stability timer from the moment it is manufactured. A powder that you reconstitute yourself allows you to control exactly when that stability timer starts running. This potentially results in a longer overall effective shelf life, since the peptide spends more of its existence in a more stable dry state before it is actually needed.
How do you turn Semax powder into a liquid?
This is simply a reconstitution process. It involves adding a measured amount of bacteriostatic water to the powder vial, gently swirling until fully dissolved, and calculating the resulting concentration based on how much total peptide was in the vial and how much water was added. This process has been discussed in detail elsewhere, but the short version is: draw up your chosen volume of water into a syringe, inject it gently down the side of the vial, not directly onto the powder, and swirl — never shake — until the solution is clear.
Is Semax available in pill or tablet form?
No. Based on available published research and standard commercial availability, Semax is not available in the form of a pill, tablet, or capsule intended for oral ingestion, in the same way that a typical medication or supplement would be taken.
Every study cited in this research collection—from the earliest Russian clinical trials to the most recent studies—used either intranasal administration (drops or spray) or, in animal studies, intraperitoneal or intranasal injection [3], [4], [5]. There are no published studies analyzing an oral formulation of Semax in the form of tablets or capsules at all.
Semax is not taken orally because it is a peptide that is degraded in the gastrointestinal tract. It is administered nasally to bypass the digestive system and enter the bloodstream directly.
The fundamental reason comes down to the basic chemistry of peptides and how the digestive system is designed to process proteins and peptides. The stomach and intestines are lined with an entire arsenal of enzymes specifically designed to break down dietary proteins into individual amino acids for absorption. After all, this is exactly how the body extracts nutrition from the protein in food. A small peptide like Semax, if swallowed, would almost certainly be broken down by these same digestive enzymes before it would have any chance of being absorbed intact into the bloodstream, let alone reaching the brain.
That is precisely why intranasal administration has been the standard route for Semax from the very beginning. It was specifically designed and tested as a way to completely circumvent this very problem of digestive degradation, delivering the peptide directly to the brain via the olfactory nerve pathway without passing through the gastrointestinal tract [6]. The entire rationale behind choosing this route of administration over oral administration was centered on avoiding gastrointestinal breakdown-intestinal degradation, which clearly tells us that an effective oral formulation was not considered a viable option by the researchers who developed Semax from the very beginning.
Would oral Semax be effective at all?
Based on general peptide pharmacology and the complete lack of studies validating the oral form, an unprotected oral Semax product would be expected to have extremely low, likely negligible, bioavailability. This means that very little, if any, of the peptide would survive digestion intact to reach the bloodstream in biologically significant amounts.
This is not a problem specific to Semax. It is a widespread and well-recognized challenge across the entire field of peptide pharmaceuticals, which is precisely why so many peptide drugs on the market—from many different companies and involving various compounds—are formulated as injections or nasal sprays rather than oral tablets. Some specialized oral peptide formulations exist for other compounds, utilizing advanced technologies such as protective coatings or absorption-enhancing carriers specifically designed to survive the intestinal environment. However, no such specialized formulation has been developed, tested, or published specifically for Semax.
What is the bioavailability of oral Semax?
No published study has measured the oral bioavailability of Semax, as no oral formulation has ever been tested. Given the general behavior of small, unprotected peptides in the gastrointestinal tract, and considering that the entire history of Semax administration is based on avoiding this exact route, any oral bioavailability would reasonably be expected to be very low. This is a conclusion based on the general pharmacology of peptides, not a directly measured finding specific to Semax. However, it is a reasonably reliable conclusion, given how consistently this pattern holds true across the broader category of unprotected peptide compounds.
Is there any interest in developing an oral form of Semax?
Nothing in the published studies indicates that an oral formulation of Semax is currently under active development. Over the decades, Russian research and clinical use have consistently focused on intranasal administration as the primary route, although injectable routes have also been studied in certain research contexts [4].
Given how effectively intranasal administration already solves the challenge of brain delivery that motivated the original development of Semax—achieving measurable brain concentrations within 2 minutes of dosing [6]—there may simply be less practical incentive to undertake the significantly more difficult engineering challenge of an effective oral formulation when a rapid, direct, and already well-characterized route of administration already exists and works well.
Disclaimer
This content is for educational and informational purposes only and should not be interpreted as medical advice, diagnosis, therapeutic recommendation, or instruction for preparing or self-administering any compound. Semax remains a research compound in most countries, including the United States and most European countries, and is not approved by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for the treatment of any medical condition. It is approved and clinically used in Russia and some Eastern European countries. Information regarding product form and specifications presented herein reflects general practices for peptide handling and formulation as described in published research and standard commercial availability, and is not intended to direct or encourage self-administration.
References
Polunin, G. S., Nurieva, S. M., Baiandin, D. L., Sheremet, N. L., & Andreeva, L. A. (2000). Evaluation of therapeutic effect of new Russian drug Semax in optic nerve disease. Ophthalmology Journal, 116(1), 15–18. PMID: 10741256
Gusev, E. I., Skvortsova, V. I., Miasoedov, N. F., Nezavibat’ko, V. N., Zhuravleva, E. Yu., & Vanichkin, A. V. (1997). Effectiveness of semax in acute period of hemispheric ischemic stroke. Journal of Neurology and Psychiatry named after S.S. Korsakov, 97(6), 26–34. PMID: 11517472
[3] Gusev, E. I., Martynov, M. Yu., Kostenko, E. V., Petrova, L. V., & Bobyreva, S. N. (2018). The efficacy of Semax in the treatment of patients at different stages of ischemic stroke. Journal of Neurology and Psychiatry named after S.S. Korsakov, 118(3), 61–68. https://doi.org/10.17116/jnevro20181183261-68
[4] Manchenko, D. M., Glazova, N. Yu., Levitskaia, N. G., Andreeva, L. A., Kamenskiĭ, A. A., & Miasoedov, N. F. (2010). Nootropic and analgesic effects of Semax following different routes of administration. I.M. Sechenov Physiological Journal of Russia, 96(10), 1014–1023. PMID: 21268834
[5] Levitskaya, N. G., Sebentsova, E. A., Andreeva, L. A., Alfeeva, L. Yu., Kamenskii, A. A., & Myasoedov, N. F. (2004). The neuroprotective effects of Semax in conditions of MPTP-induced lesions of the brain’s dopaminergic system. Neuroscience and Behavioral Physiology, 34(4), 399–405. https://doi.org/10.1023/b:neab.0000018752.59465.28
[6] Shevchenko, K. V., Nagaev, I. Yu., Alfeeva, L. Yu., Andreeva, L. A., Kamenskiĭ, A. A., Levitskaia, N. G., Shevchenko, V. P., Grivennikov, I. A., & Miasoedov, N. F. (2006). Kinetics of Semax penetration into the brain and blood of rats following intranasal administration. Bioorganic Chemistry, 32(1), 64–70. https://doi.org/10.1134/s1068162006010055